Transfusion of plasma: Products - Indications;Transfusion de plasma : Produits-indications

Transfusion Clinique et Biologique

Volumn 20, Issue 2, 2013, Pages 47-54

  Djoudi, R ^a  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Coagulant factors; Fresh frozen plasma; Guidelines; Haemorrhage; Massive transfusion; Therapeutic plasma

Indexed keywords

BLOOD CLOTTING FACTOR; FIBRINOGEN; FRESH FROZEN PLASMA; INFUSION FLUID; PROTHROMBIN COMPLEX;

BLEEDING TENDENCY; BLOOD SAFETY; BLOOD TRANSFUSION; CLINICAL PROTOCOL; FRANCE; INFECTION PREVENTION; PHYSICIAN; PRACTICE GUIDELINE; RISK ASSESSMENT; SHORT SURVEY; TREATMENT INDICATION;

ANTICOAGULANTS; BLOOD COMPONENT TRANSFUSION; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; COAGULATION PROTEIN DISORDERS; DISSEMINATED INTRAVASCULAR COAGULATION; HEMORRHAGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; LIVER FAILURE; LIVER TRANSPLANTATION; PLASMA; PLASMA EXCHANGE; POSTOPERATIVE HEMORRHAGE; THROMBOTIC MICROANGIOPATHIES;

EID: 84878115293     PISSN: 12467820     EISSN: 19538022     Source Type: Journal    
DOI: 10.1016/j.tracli.2013.02.005     Document Type: Short Survey

References (58)

1. Rapport activité de l'EFS. Année 2011. http://www.dondusang.net/rewrite/article/4900/l-efs/publications/feuilletez-en-ligne-le-rapport-d-activite-2011-de-l-efs.htm%3FidRubrique=790.
2. Kakkar N., Kaur R., Dhanoa J. Improvement in fresh frozen plasma transfusion practice: results of an outcome audit. Transfusion Med 2004, 14:231-235.
3. Arrêté du 13 juillet 2011 abrogeant l'arrêté du 3 décembre 1991 relatif à l'utilisation du plasma congelé. Journal Officiel, 23 juillet 2011, texte 18.
4. Recommandations de l'ANSM sur le plasma thérapeutique, juin 2012. http://ansm.sante.fr/S-informer/Points-d-information-Points-d%20information/Transfusion-de-plasma-therapeutique-Produits-indications-Actualisation-2012-des-recommandations-%20Point-d-info.
5. Décision du 20 octobre 2010 fixant la liste et les caractéristiques des produits sanguins labile. Journal Officiel, 28 novembre 2010, texte 12.
6. Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011, 100:169-178.
7. Sachs U.J. Non-infectious serious hazards in plasma transfusion. Transfus Apher Sci 2010, 43:381-386.
8. Shanwell A., Andersson T.M.L., Rostgaard K., Edgren G., Hjalgrim H., Norda R., et al. Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma. Vox Sang 2009, 96:316-323.
9. Inaba K., Branco B.C., Rhee P., Holcomb J.B., Blackbourne L.H., Shulman I., et al. Impact of ABO-Identical vs ABO-compatible non identical plasma transfusion in trauma patients. Arch Surg 2010, 145:899-906.
10. Taraldsrud E., Kjollesdal K.S., Pripp A.H., Solheim B.G. ABO identical versus ABO compatible plasma transfusions. Vox Sang 2012, 103:177-178.
11. Arrêté du 30 décembre 1992 interdisant la délivrance d'un produit sanguin humain à usage thérapeutique. Journal Officiel, NOR: SANP9203357A.
12. The collection, testing and use of blood and blood components in Europe. 2008 Report. Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM). Council of Europe, May 2011.
13. Report of the US Department of Health and Human Services. The 2009 national blood collection and utilization survey report 2011. Washington, DC: US Department of Health and Human Services.
14. Hellstern P., Solheim B.G. The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus Med Hemother 2011, 38:65-70.
15. Flamholz R., Jeon H.R., Baron J.M., Baron B.W. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses. J Clin Apher 2000, 15:169-172.
16. Williamson L.M., Llewelyn C.A., Fisher N.C., Allain J.P., Bellamy M.C., Baglin T.P., et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 1999, 39:1227-1234.
17. Martinaud C., Civadier C., Ausset S., Verret C., Deshayes A.V., Sailliol A. In vitro hemostatic properties of French lyophilized plasma. Anesthesiology 2012, 117:339-346.
18. Pandey S., Vyas G.N. Adverse effects of plasma transfusion. Transfusion 2012, 52. 65S-79S.
19. Narick C., Triulzi D.J., Yazer M.H. Transfusion-associated circulatory overload after plasma transfusion. Transfusion 2012, 52:160-165.
20. Rapport d'activité hémovigilance 2011. Agence national de sécurité du médicament et des produits de santé (ANSM). Juillet 2012. http://ansm.sante.fr/var/ansm_site/storage/original/application/94eaed87fcb1d3c9d2187f4945256875.pdf.
21. Bost V., Odent-Malaure H., Chavarin P., Benamara H., Fabrigli P., Garraud O. A regional haemovigilance retrospective study of four types of therapeutic plasma in a ten-year survey period in France. Vox Sang 2013, 10.1111/vox.12007.
22. Funk M.B., Lohmann A., Guenay S., Henseler O., Heiden M., Hanschmann K.M., et al. Transfusion-transmitted bacterial infections - haemovigilance data of German blood establishments (1997-2010). Transfus Med Hemother 2011, 38:266-271.
23. Hacquard M., Lecompte T., Belcour B., Geschier C., Jacquot C., Jacquot E., et al. Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen-reduced plasmas. Vox Sang 2012, 102:354-361.
24. Bartelmaos T., Chabanel A., Léger J., Villalon L., Gillon M.C., Rouget C., et al. Plasma transfusion in liver transplantation: a randomized, double-blind, multicenter clinical comparison of three virally secured plasmas. Transfusion 2012, 10.1111/j.1537-2995.2012.03895.x.
25. Lerner R.G., Nelson J., Sorcia E., Grima K., Kancherla R.R., Zarou-Naimo C.M., et al. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang 2000, 79:161-167.
26. Horowitz M.D., Pehta J.C. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. 25th Congress of the International Society of Blood Transfusion. Oslo, Norway, June 27-July 2, 1998. Vox Sang 1998, 74. abstract 6.
27. Freeman J.W., Williamson L.M., Llewelyn C., Fisher N., Allain J.P., Bellamy M., et al. A randomized trial of solven/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during orthoptopic liver transplantation. 25th Congress of the International Society of Blood Transfusion. Oslo, Norway, June 27-July 2, 1998. Vox Sang 1998, 74. abstract 5.
28. Mintz P.D., Bass N.M., Petz L.D., Steadman R., Streiff M., McCullough J., et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006, 107:3753-3760.
29. Mintz P.D., Neff A., MacKenzie M., Goodnough L.T., Hillyer C., Kessler C., et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 2006, 46:1693-1704.
30. Iorio A., Basileo M., Marchesini E., Materazzi M., Marchesi M., Esposito A., et al. The good use of plasma. A critical analysis of five international guidelines. Blood Transfus 2008, 6:18-24.
31. Vlaar A.P., in der Maur A.L., Binnekade J.M., Schultz M.J., Juffermans N.P. A survey of physicians' reasons to transfuse plasma and platelets in the critically ill: a prospective single-centre cohort study. Transfus Med 2009, 19:207-212.
32. Luk C., Eckert K.M., Barr R.M., Chin-Yee I.H. Prospective audit of the use of fresh-frozen plasma, based on Canadian Medical Association transfusion guidelines. Can Med Assoc J 2002, 166:1539-1540.
33. Puetz J., Witmer C., Huang Y.S., Raffini L. Widespread use of fresh frozen plasma in US children's hospitals despite limited evidence demonstrating a beneficial effect. J Pediatr 2012, 160:210-215.
34. Stanworth S.J., Grant-Casey J., Lowe D., Laffan M., New H., Murphy M.F., et al. The use of fresh-frozen plasma in England: high levels of inappropriate use in adults and children. Transfusion 2011, 51:62-70.
35. Ciavarella D., Reed R.L., Counts R.B., Baron L., Pavlin E., Heimbach D.M., et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987, 67:365-368.
36. Hiippala S.T., Myllylä G.J., Vahtera E.M. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995, 81:360-365.
37. Callum J.L., Rizoli S. Plasma transfusion for patients with severe hemorrhage: what is the evidence?. Transfusion 2012, 52. 30S-7S.
38. Rossaint R., Bouillon B., Cerny V., Coats T.J., Duranteau J., Fernández-Mondéjar E., et al. Management of bleeding following major trauma: an updated European guideline. Crit Care 2012, 114:R52.
39. Charbit B., Mandelbrot L., Samain E., Baron G., Haddaoui B., Keita H., et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007, 5:266-273.
40. Sørensen B., Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010, 149:834-843.
41. Toulon P., Ozier Y., Ankri A., Fléron M.H., Leroux G., Samama C.M. Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study. Thromb Haemost 2009, 101:394-401.
42. Weber C.F., Görlinger K., Meininger D., Herrmann E., Bingold T., Moritz A., et al. A prospective randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012, 117:531-547.
43. Bolliger D., Seeberger M.D., Tanaka K.A. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev 2012, 26:1-13.
44. Brohi K., Singh J., Mischa H., Coats T. Acute traumatic coagulopathy. J Trauma Inj Infect Crit Care 2003, 54:1127-1130.
45. Bhangu A., Nepogodiev D., Doughty H., Bowley D.M. Meta-analysis of plasma to red blood cell ratios and mortality in massive blood transfusions for trauma. Injury 2012, 10.1016/j.injury.2012.07.193.
46. Rajasekhar A., Gowing R., Zarychanski R., Arnold D., Lim W., Crowther M.A., et al. Survival of trauma patients after massive red blood cell transfusion using a high or low red blood cell to plasma transfusion ratio. Crit Care Med 2011, 39:1507-1513.
47. Sambasivan C.N., Kunio N.R., Nair P.V., Zink K.A., Michalek J.E., Holcomb J.B., et al. High ratios of plasma and platelets to packed red blood cells do not affect mortality in nonmassively transfused patients. J Trauma Inj Infect Crit Care 2011, 71:S329-S336.
48. Tripodi A., Salerno F., Chantarangkul V., Clerici M., Cazzaniga M., Primignani M., et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005, 41:553-558.
49. Segal J.B., Dzik W.H., Transfusion Medicine/Hemostasis Clinical Trials Network Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005, 45:1413-1425.
50. Massicotte L., Denault A.Y., Beaulieu D., Thibeault L., Hevesi Z., Nozza A., et al. Transfusion rate for 500 consecutive liver transplantations: experience of one liver transplantation center. Transplantation 2012, 93:1276-1281.
51. Stanworth S.J., Brunskill S.J., Hyde C.J., McClelland D.B.L., Murphy M.F. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004, 26:139-152.
52. Yang L., Stanworth S., Hopewell S., Doree C., Murphy M. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion 2012, 52:1673-1686.
53. Rahe-Meyer N., Solomon C., Hanke A., Schmidt D.S., Knoerzer D., Hochleitner G., et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013, 118:40-50.
54. Rock G.A., Shumak K.H., Buskard N.A., Blanchette V.S., Kelton J.G., Nair R.C., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991, 325:393-397.
55. Lubetsky A., Yonath H., Olchovsky D., Loebstein R., Halkin H., Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 2003, 163:2469-2473.
56. Demeyere R., Gillardin S., Arnout J., Strengers P.F.W. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010, 99:251-260.
57. Rideau C., Gaertner E., Blay M., Trojani C., Toulon P. Successful management of fresh-frozen plasma transfusion therapy based upon clinical symptoms for total knee arthroplasty in a patient with severe factor V deficiency. Haemophilia 2010, 16:381-383.
58. de Alarcon P., Benjamin R., Dugdale M., Kessler C., Shopnick R., Smith P., et al. Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies. Transfusion 2005, 45:1362-1372.